Elanco Animal Health (ELAN) Issues Innovation Update

Elanco Animal Health Incorporated (NYSE: ELAN) today announced updates to the expected U.S. Food and Drug Administration (FDA) approval timelines for Zenrelia and Credelio Quattro.

For Zenrelia, the company has received confirmation from FDA that all major technical sections (Effectiveness, Safety and Chemistry, Manufacturing, and Controls (CMC)) are complete as of late June. For the Labeling minor technical section, earlier this week the Company aligned with FDA on the language and expects to receive the completion letter by mid-July. The 60-day final administrative review will follow, placing expected approval late in the third quarter of 2024. The company now anticipates a U.S. launch for Zenrelia in the fourth quarter of 2024.

"Elanco continues to view Zenrelia as positively differentiated for effectiveness and convenience, which we believe can address unmet needs in the market. However, we expect the U.S. label will include a boxed warning on safety based on the outcome of a trial with unvaccinated dogs dosed at 3x the label dose," said Bobby Modi, Elanco Executive Vice President U.S. Pet Health and Global Digital Transformation. "While we remain confident in Zenrelia's blockbuster potential, we believe this warning will slow the product adoption curve in the U.S. and initially limit the number of expected treatment days by approximately 25%. We plan to conduct additional research to support an improved label over time."

Zenrelia has also received its first approval in Brazil by the Brazilian Minister of Agriculture, Livestock and Food Supply, with launch planned for the fourth quarter of 2024. Additional reviews are ongoing in other markets, including Canada, Europe and Japan.

For Credelio Quattro, two of three major technical sections – Effectiveness and Safety – are complete, however, in June, the Company received an incomplete letter for the CMC major technical section. Elanco has already submitted its response to the two questions in the letter, which did not require any additional data generation. The FDA has offered a shortened, 60-day review timeline for Elanco's response. Following this, the minor technical section reviews will be completed, including Labeling. The product is then expected to go through the 60-day final administrative review, placing the expected approval in the fourth quarter of 2024, with U.S. launch expected in the first quarter of 2025. The Company continues to expect positive differentiation related to effectiveness.

"We have a robust innovation portfolio and continue to expect to deliver $600 to $700 million of Innovation sales by the end of 2025," said Jeff Simmons, Elanco President and CEO. "With the expected launches of Bovaer and Zenrelia in the second half and the continued strong performance of Experior and AdTab, we are increasing our expectations of Innovation sales in 2024 from $375 to $410 million to $400 to $450 million."

On the second quarter earnings call, the Company will update 2024 financial guidance for revenue, adjusted EBITDA, adjusted EPS and other key metrics, including reflecting the sale of the aqua business, with continued expectation of a close around mid-year.

The FDA has the legal authority to approve and regulate drugs for both people and animals. FDA's Center for Veterinary Medicine (CVM) approves and regulates new animal drugs. The approval process includes up to five major technical sections (Target Animal Safety; Effectiveness; Chemistry, Manufacturing, and Controls; Human Food Safety (farm animal products); and Environmental Impact (farm animal products) and two minor technical sections (All Other Information and Labeling)). Once all the major and minor technical sections are complete, the drug sponsor submits the New Animal Drug Application (NADA), for the final administrative review. For more information about the FDA approval process, please visit: https://www.fda.gov/animal-veterinary/animal-health-literacy/idea-marketplace-journey-animal-drug-through-approval-process.

You May Also Be Interested In